Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer-Reference-Cited by-同舟云学术

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

Published:2014-06-20 Issue:5 Volume:32 Page:955-968
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Calvo Emiliano,Chen Victor J.,Marshall Mark,Ohnmacht Ute,Hynes Scott M.,Kumm Elizabeth,Diaz H. Bruce,Barnard Darlene,Merzoug Farhana F.,Huber Lysiane,Kays Lisa,Iversen Philip,Calles Antonio,Voss Beatrice,Lin Aimee Bence,Dickgreber Nicolas,Wehler Thomas,Sebastian Martin

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-014-0114-5.pdf

Reference37 articles.

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917

2. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, Thibodeau S, Adjei AA, Jett J, Deschamps C (2005) Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 128(1):452–462

3. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13(3):247–255

4. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clini Oncol 26(21):3543–3551

5. Manegold C, Gatzemeier U, von Pawel J, Pirker R, Malayeri R, Blatter J, Krejcy K (2000) Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Annals of Oncol 11(4):435–440

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity;Nature Communications;2024-05-31

2. Targeting the DNA Damage Response for Cancer Therapy;International Journal of Molecular Sciences;2023-11-02

3. Double‐strand DNA break repair: molecular mechanisms and therapeutic targets;MedComm;2023-10

4. CHK1 Inhibition Overcomes Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell A549;2022-11-02

5. CHK1 Inhibition Overcomes Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell A549;2022-09-09